rs11644424 CDH13 hair loss and gene expression
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- rs11644424 is linked to hair loss during breast cancer chemotherapy
- The variant raises CDH13 activity in artery tissue
- It has been studied in about 91 patients with a strong statistical signal
Key takeaways rs11644424 is linked to hair loss during breast cancer chemotherapy The variant raises CDH13 activity in artery tissue It has been studied in about 91 patients with a strong statistical signal
What the research says The GWAS catalog reports that rs11644424 is associated with a higher risk of hair loss during chemotherapy for breast cancer in about 91 patients [PMID 24025145]. CDH13 expression rises in artery tissue when this variant is present, showing a modest increase in gene activity [GTEx].
Reported associations Adverse response to chemotherapy: the variant is linked to hair loss during breast cancer treatment with cyclophosphamide and doxorubicin plus 5FU, reported effect size 3.32 p=8e-6 in about 91 people [PMID 24025145]. CDH13 expression: the variant is associated with higher CDH13 activity in artery tissue, reported slope +0.22 p=3.0e-8 [GTEx].
Evidence quality The GWAS involves about 91 individuals and reports a strong statistical signal with p=8e-6 but no replication data are provided.
Tissue-specific expression effects
- CDH13: increased expression in artery_tibial tissue [GTEx Portal]
Lifestyle considerations No lifestyle considerations on file for this variant.
Frequently asked questions
What does the rs11644424 CDH13 variant do?
It is associated with hair loss during breast cancer chemotherapy and it increases CDH13 activity in artery tissue.
Is this variant linked to any other health issues?
The evidence only shows a connection to chemo-induced hair loss and higher CDH13 expression; no other traits are reported.
Can I test for this variant?
Yes, it can be included in standard genetic panels that cover breast cancer risk genes.